MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Aripiprazole (Abilify®)

Selected References:

  • Andrade C. 2021. Major congenital malformations associated with exposure to second-generation antipsychotic drugs during pregnancy. J Clin Psychiatry 82:5.
  • Bellet F. et al. 2015. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiology and Drug Safety 24:368-380.
  • Bonari L, et al. 2004. Perinatal Risks of Untreated Depression During Pregnancy. Can J Psychiatry. 49(11):726-735.
  • Cuomo A, et al. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. Journal of Affective Disorders 228;229-237.
  • Damkier P, Videbech P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs 32(4):351-366.
  • 2014. ABILIFY (aripiprazole).
  • Fernandez-Abascal B et al. (2021). Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Ther Adv Psychopharmacol. 11: 2045125321991277. doi: 10.1177/2045125321991277.
  • Freeman, MP, et al. 2021. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health 24, 659–667. https://doi.org/10.1007/s00737-021-01115-6.
  • Galbally M et al. 2018. Ariprazole and pregnancy: A retrospective, multicenter study. J Affect Disord 238:593-596.
  • Habermann F. et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. Journal of Clinical Psychopharmacology 33(4):453-462.
  • Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry 1;73(9):938-46.
  • Lutz UC, et al. 2010. Aripiprazole in pregnancy and lactation: a case report. Journal of Clinical Psychopharmacology 30:205-205.
  • Mendhekar DN, et al. 2006. Aripiprazole use in pregnant schizoaffective woman. Bipolar Disorder 8:229-300.
  • Morin C, Chevalier I. 2017. Severe hypernatremic dehydration and lower limb gangrene in an infant exposed to lamotrigine, aripiprazole, and sertraline in breast milk. Breastfeed Med 12:377-80
  • Naughton S, et al. 2023. Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers. Australasian Psychiatry. 31(2):201-204. doi:10.1177/10398562231159510.
  • Nordeng H, et al. 2014. Transfer of aripiprazole to breast milk: a case report. Journal of Clinical Psychopharmacology 34(2):272-75.
  • Sakai T, et al. 2017. Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of Paulus WE. 2013. Is the Japanese Adverse Drug Event Report Database. Drug Saf. 40(11):1141-1146
  • Salvatore, G. 2014. A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Drug Safety Evaluation 13(12):1733-1742.
  • Schlotterbeck P, et al. 2007. Aripiprazole in Human Milk. International Journal of Neuropsychopharmacology 10:433.
  • Walker T, et al. 2019. Low dose Abilify (aripiprazole) in combination with Effexor XR (venlafaxine HCl) resulted in cessation of lactation. Clin Lact 10:56-9.
  • Straub L, et al. 2022. Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. JAMA Intern Med. 182(5):522–533. doi:10.1001/jamainternmed.2022.0375.
  • Watanabe N, et al. 2011. Perinatal use of aripiprazole: a case report. Journal of Clinical Psychopharmacology 31(3):377-9.
  • Yskes R, et al. 2018. A case of decreased milk production associated with aripiprazole. Prim Care Companion CNS Discord 20(6):18102303.
  • Zheng L et al. 2021. Dose adjustment of quetiapine and aripiprazole for pregnant women using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet; May;60 (5):623-635

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.